Evidence map›Paper›PMID 32383555›Full record

ArticleESC heart failure2020

The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure.

Ross T Campbell, Adam Jasilek, Harald Mischak, Esther Nkuipou-Kenfack, Agnieszka Latosinska, Paul I Welsh, Colette E Jackson, Jane Cannon, Alex McConnachie, Christian Delles and 1 more

Open access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Cardiovascular Aging.Reviews in cardiovascular medicine · 2025
    Review
  3. Article
  4. Biomarkers of aging.Science China. Life sciences · 2023
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Ross T CampbellInstitute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, UK.
Adam JasilekRoberson Centre for Biostatistics, University of Glasgow, Glasgow, UK.
Harald MischakInstitute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, UK.
Esther Nkuipou-KenfackMosaiques Diagnostics GmbH, Hannover, Germany.
Agnieszka LatosinskaMosaiques Diagnostics GmbH, Hannover, Germany.
Paul I WelshInstitute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, UK.
Colette E JacksonQueen Elizabeth University Hospital, Glasgow, UK.
Jane CannonHarefield Hospital, Harefield, London, UK.
Alex McConnachieRoberson Centre for Biostatistics, University of Glasgow, Glasgow, UK.
Christian DellesInstitute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, UK.
John J V McMurrayInstitute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, UK.
University of Glasgow · GBMosaiques Diagnostics and Therapeutics (Germany) · DEHarefield Hospital · GBQueen Elizabeth University Hospital · GB

Funding

British Heart Foundation PG/13/17/30050British Heart Foundation RE/13/5/30177British Heart Foundation RE/18/6/34217British Society of Heart FailureChief Scientist Office CZH/4/439European Commission HEALTH-FP7-305507
6 · The paper itself

Abstract

aimsMeasurement of B-type natriuretic peptide (BNP) or N-terminal pro-BNP is recommended as part of the diagnostic workup of patients with suspected heart failure (HF). We evaluated the diagnostic and prognostic utility of the novel urinary proteomic classifier HF1, compared with BNP, in HF. HF1 consists of 85 unique urinary peptide fragments thought, mainly, to reflect collagen turnover. METHODS AND

resultsWe performed urinary proteome analysis using capillary electrophoresis coupled with mass spectrometry in 829 participants. Of these, 622 had HF (504 had chronic HF and 118 acute HF) and 207 were controls (62 coronary heart disease patients without HF and 145 healthy controls). The area under the receiver operating characteristic (ROC) curve (AUC) using HF1 for the diagnosis of HF (cases vs. controls) was 0.94 (95% CI, 0.92-0.96). This compared with an AUC for BNP of 0.98 (95% CI, 0.97-0.99). Adding HF1 to BNP increased the AUC to 0.99 (0.98-0.99), P < 0.001, and led to a net reclassification improvement of 0.67 (95% CI, 0.54-0.77), P < 0.001. Among 433 HF patients followed up for a median of 989 days, we observed 186 deaths. HF1 had poorer predictive value to BNP for all-cause mortality and did not add prognostic information when combined with BNP.

conclusionsThe urinary proteomic classifier HF1 performed as well, diagnostically, as BNP and provided incremental diagnostic information when added to BNP. HF1 had less prognostic utility than BNP.

Indexed as

Heart FailureNatriuretic Peptide, BrainBiomarkersHumansPrognosisProteomicsBiomarkersNatriuretic Peptide, BrainBiomarkersCollagenDiagnosisHeart failurePrognosisProteomics

Identifiers

PMID32383555
PMCPMC7373887
OpenAlexW3021895661

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.